Funder
National Natural Science Foundation of China
Natural Science Foundation of Hunan Province
the Key Research and Development Project of Hunan Province
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Oncology
Reference25 articles.
1. Arboleda MJ, Lyons JF, Kabbinavar FF, Bray MR, Snow BE, Ayala R, Danino M, Karlan BY, Slamon DJ (2003) Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res 63(1):196–206
2. Farmahini Farahani M, Maghzi P, Jafari Aryan N, Payandemehr B, Soni M, Azhdarzadeh M (2020) A randomized, double-blind, parallel pharmacokinetic study comparing the trastuzumab biosimilar candidate, AryoTrust®, and reference trastuzumab in healthy subjects. Expert Opin Investig Drugs 29(12):1443–1450. https://doi.org/10.1080/13543784.2020.1831470
3. Li BT, Shen R, Buonocore D, Olah ZT, Ni A, Ginsberg MS, Ulaner GA, Offin M, Feldman D, Hembrough T, Cecchi F, Schwartz S, Pavlakis N, Clarke S, Won HH, Brzostowski EB, Riely GJ, Solit DB, Hyman DM, Drilon A, Rudin CM, Berger MF, Baselga J, Scaltriti M, Arcila ME, Kris MG (2018) Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. J Clin Oncol 36(24):2532–2537. https://doi.org/10.1200/jco.2018.77.9777
4. Hudis CA (2007) Trastuzumab–mechanism of action and use in clinical practice. N Engl J Med 357(1):39–51. https://doi.org/10.1056/NEJMra043186
5. Ballantyne A, Dhillon S (2013) Trastuzumab emtansine: first global approval. Drugs 73(7):755–765. https://doi.org/10.1007/s40265-013-0050-2